NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-HG-17-014 from the NIH Guide for Grants and Contracts
Notice NOT-NS-17-039 from the NIH Guide for Grants and Contracts
Notice NOT-NS-18-001 from the NIH Guide for Grants and Contracts
Notice NOT-CA-17-079 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-17-454 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to promote systems developmental biology. In the context of this FOA, systems developmental biology is defined as research focused on understanding how biological components work together to produce the complex biological phenomena encompassing embryonic development.
Notice NOT-MH-17-041 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-17-450 from the NIH Guide for Grants and Contracts. The Lasker Clinical Research Scholars Program supports research activities during the early stage careers of independent clinical researchers. This FOA offers the opportunity for current Lasker awardees (Si2) to apply for the transition phase (R00) of the program. In the R00 phase, successful Si2 scholars will receive up to 5 years of NIH support for their research at an extramural research facility.
Notice NOT-AA-17-010 from the NIH Guide for Grants and Contracts
Notice NOT-AG-17-014 from the NIH Guide for Grants and Contracts
Notice NOT-AA-17-009 from the NIH Guide for Grants and Contracts
Notice NOT-RM-17-036 from the NIH Guide for Grants and Contracts
Notice NOT-DA-17-052 from the NIH Guide for Grants and Contracts
Notice NOT-AA-17-011 from the NIH Guide for Grants and Contracts
Notice NOT-EB-17-009 from the NIH Guide for Grants and Contracts
Notice NOT-HD-17-019 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-RM-17-029 from the NIH Guide for Grants and Contracts. The Common Fund Program - Accelerating Translation of Glycoscience: Integration and Accessibility - aims to develop accessible and affordable new tools and technologies for studying carbohydrates that will allow biomedical researchers to significantly advance our understanding of the roles of these complex molecules in health and disease. This program will enable investigators who might not otherwise conduct research in the glycosciences, to undertake the study of carbohydrate structure and function.
Funding Opportunity RFA-RM-17-030 from the NIH Guide for Grants and Contracts. The Common Fund Program - Accelerating Translation of Glycoscience: Integration and Accessibility - aims to develop accessible and affordable new tools and technologies for studying carbohydrates that will allow biomedical researchers to significantly advance our understanding of the roles of these complex molecules in health and disease. This program will enable investigators who might not otherwise conduct research in the glycosciences, to undertake the study of carbohydrate structure and function.
Funding Opportunity PA-17-449 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to stimulate research in the interplay between cell death pathways in nave and drug resistant cancers. Regulated cell death, especially apoptosis and necroptosis, are natural barriers that restrict malignant cells from surviving and disseminating. Evasion of cell death mechanisms is one of the hallmarks of cancer contributing to tumor progression, metastases and resistance to therapy. Recent studies show that the machinery to activate different forms of cell death coexists in cells but the crosstalk of cell death pathways in cancer has not been systematically studied. Research into the intersection of cell death programs will allow for better defining markers of cell death pathway at the molecular level and offers the possibility that the specific mediators of cell survival may be inhibited and/or the mediators of cell death enhanced, driving nave and drug resistant cancer cells toward effective cell death.
Funding Opportunity PA-17-440 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to stimulate research in the interplay between cell death pathways in nave and drug resistant cancers. Regulated cell death, especially apoptosis and necroptosis, are natural barriers that restrict malignant cells from surviving and disseminating. Evasion of cell death mechanisms is one of the hallmarks of cancer contributing to tumor progression, metastases and resistance to therapy. Recent studies show that the machinery to activate different forms of cell death coexists in cells but the crosstalk of cell death pathways in cancer has not been systematically studied. Research into the intersection of cell death programs will allow for better defining markers of cell death pathway at the molecular level and offers the possibility that the specific mediators of cell survival may be inhibited and/or the mediators of cell death enhanced, driving nave and drug resistant cancer cells toward effective cell death.
Funding Opportunity PAR-17-441 from the NIH Guide for Grants and Contracts. This FOA will support exploratory/developmental research programs of interest to the NIBIB (https://www.nibib.nih.gov/research-funding). These studies are expected to lead to breakthroughs in development of innovative techniques, agents, methodologies, models, or their applications. These studies may involve considerable risk that should be balanced by the potential high impact on human-health and related research. Applicants are expected to propose novel biomedical research approaches for which there is no preliminary data to demonstrate the feasibility of the proposed project. A project may be exploratory, developmental, proof of concept, or high risk-high impact, and may be technology design-directed, discovery-driven, or hypothesis-driven.